Search
DFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic
Hydrogen fluoride
go.drugbank.com/drugs/DB11072ApprovedInvestigationalIt is used as a chemical reagent in several industrial processes such as oil refinery. It is also used as etchant, cleaning agent, and a reagent to dissolve oxides and silicates.
Ritodrine
go.drugbank.com/drugs/DB00867ApprovedWithdrawnAdrenergic beta-agonist used to control premature labor.
Indium In-111 satumomab pendetide
go.drugbank.com/drugs/DB00057ApprovedWithdrawnTumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint®) is no longer commercially available.
Synonyms: Indium In 111 satumomab pendetideKC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascula...
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424InvestigationalMVA-BN-brachyury-TRICOM vaccine is an investigational cancer vaccine. … [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.
Synonyms: MVA-BN-Brachyury, MVA-BN-Brachyury Prime VaccineSCIB1
go.drugbank.com/drugs/DB18439InvestigationalSCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.
Cimetropium
go.drugbank.com/drugs/DB09271InvestigationalIt has never been approved for use in the U.S. or Canada. … It is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity.
Nisoxetine
go.drugbank.com/drugs/DB09186ExperimentalNisoxetine is a selective norepinephrine reuptake inhibitor (SNRI) developed in the 1970s. … It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI.